Mineralocorticoid receptor antagonists significantly reduced pulse wave velocity compared with control (MD -0.75 m/s; 95% CI -1.12 to -0.39; P<0.00001).
Meta-Analysis (n=515)
Does mineralocorticoid receptor antagonist therapy improve arterial stiffness and endothelial function compared to control?
MRA therapy significantly improves surrogate markers of arterial stiffness and endothelial function, independent of its blood pressure-lowering effects.
Effect estimate: MD -0.75 m/s (95% CI -1.12 to -0.39)
p-value: p=<0.00001
Although numerous studies have confirmed the beneficial effects of pharmacological therapy for arterial stiffness and endothelial dysfunction, which are predictors/therapeutic targets for cardiovascular diseases, only a few overall quantitative evaluations of MRAs (mineralocorticoid receptor antagonists) exist. We searched PubMed and Cochrane CENTRAL (Cochrane Central Register of Controlled Trials) for randomized trials evaluating MRA effects on arterial stiffness measured by pulse wave velocity (PWV) or augmentation index and endothelial function measured by flow-mediated dilation. Data from the included trials were pooled by using random-effects meta-analysis of the weighted mean difference (MD) between the comparator groups. The primary outcome was the MD of PWV. In 11 trials including 515 patients, the MRA treatment reduced the PWV when compared with control (MD, −0.75 m/s 95% CI, −1.12 to −0.39, P <0.00001), without heterogeneity. There were comparable effects of MRA on carotid-femoral PWV and those on other forms of PWV ( P =0.705 for heterogeneity). The effects of MRA on PWV were independent of blood pressure reduction related to the treatment according to meta-regression analysis. The MRA treatment reduced the augmentation index compared with control in 5 trials including 283 patients (MD, −6.74% 95% CI, −10.26 to −3.21, P =0.0002) and increased the flow-mediated dilation in 11 trials including 570 patients (MD, 1.18% 95% CI, 0.14 to 2.23, P =0.03). In conclusion, the current meta-analysis demonstrates the beneficial effects of MRA on PWV, augmentation index, and flow-mediated dilation.
Sakima et al. (Tue,) conducted a meta-analysis in Arterial stiffness and endothelial dysfunction (n=515). Mineralocorticoid receptor antagonists (MRAs) vs. Control was evaluated on Mean difference of pulse wave velocity (PWV) (MD -0.75 m/s, 95% CI -1.12 to -0.39, p=<0.00001). Mineralocorticoid receptor antagonists significantly reduced pulse wave velocity compared with control (MD -0.75 m/s; 95% CI -1.12 to -0.39; P<0.00001).